Resting State BOLD Variability Is Linked to White Matter Vascular Burden in Healthy Aging but Not in Older Adults With Subjective Cognitive Decline
| dc.contributor.author | Scarapicchia, Vanessa | |
| dc.contributor.author | Garcia-Barrera, Mauricio A. | |
| dc.contributor.author | MacDonald, Stuart W. S. | |
| dc.contributor.author | Gawryluk, Jodie R. | |
| dc.date.accessioned | 2021-10-01T21:06:11Z | |
| dc.date.available | 2021-10-01T21:06:11Z | |
| dc.date.copyright | 2019 | en_US |
| dc.date.issued | 2019 | |
| dc.description.abstract | Background: Alzheimer’s disease (AD) is the leading cause of dementia. A lack of curative treatments and a rapidly aging global population have amplified the need for early biomarkers of the disease process. Recent advances suggest that subjective cognitive decline (SCD) may be one of the earliest symptomatic markers of the AD cascade. Previous studies have identified changes in variability in the blood-oxygenlevel-dependent (BOLD) signal in patients with AD, with a possible association between BOLD variability and cerebrovascular factors in the aging brain. The objective of the current study was to determine whether changes in BOLD variability can be identified in individuals with SCD, and whether this signal may be associated with markers of cerebrovascular integrity in SCD and older adults without memory complaints. Method: Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database from 19 participants with SCD and 19 similarly-aged controls. For each participant, a map of BOLD signal variability (SDBOLD) was computed as the standard deviation of the BOLD time-series at each voxel. Group comparisons were performed to examine differences in resting-state SDBOLD in SCD vs. healthy controls. Relationships were then examined between participant SDBOLD maps and neuroimaging markers of white matter vascular infarcts in each group separately. Results: Between-group comparisons showed no significant differences in wholebrain SDBOLD in individuals with SCD and controls. In the healthy aging group, higher white matter hyperintensity (WMH) burden was associated with greater SDBOLD in right temporal regions (p < 0.05), and lower scores on a measure of global executive functioning. These associations were not identified in individuals with SCD. Conclusion: The current study underscores previous evidence for a relationship between SDBOLD and white matter vascular infarcts in the healthy aging brain. The findings also provide evidence for a dissociable relationship between healthy aging and SCD, such that in healthy controls, increased WMH is associated with declines in executive function that is not observed in older adults who present with memory complaints. Further multimodal work is needed to better understand the contributions of vascular pathology to the BOLD signal, and its potential relationship with pathological aging. | en_US |
| dc.description.reviewstatus | Reviewed | en_US |
| dc.description.scholarlevel | Faculty | en_US |
| dc.description.sponsorship | This project was supported by funding from the Natural Sciences and Engineering Research Council of Canada. Funding for this project was made possible by generous support from the Fonds de recherche du Québec—Santé (FRQS). Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81xWH- 12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol- Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Limited and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Limited; Janssen Alzheimer Immunotherapy Research and Development, LLC.; Johnson and Johnson Pharmaceutical Research and Development LLC.; Lumosity; Lundbeck; Merck and Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. | en_US |
| dc.identifier.citation | Scarapicchia, V., Garcia-Barrera, M., Macdonald, S.W.S., & Gawryluk, J.R. (2019). Resting State BOLD Variability Is Linked to White Matter Vascular Burden in Healthy Aging but Not in Older Adults With Subjective Cognitive Decline. Frontiers in Human Neuroscience, 13(429). https://doi.org/10.3389/fnhum.2019.00429 | en_US |
| dc.identifier.uri | https://doi.org/10.3389/fnhum.2019.00429 | |
| dc.identifier.uri | http://hdl.handle.net/1828/13425 | |
| dc.language.iso | en | en_US |
| dc.publisher | Frontiers in Human Neuroscience | en_US |
| dc.subject | signal variability | |
| dc.subject | Alzheimer's disease | |
| dc.subject | subjective cognitive decline | |
| dc.subject | cerebrovascular health | |
| dc.subject | aging | |
| dc.subject | biomarkers | |
| dc.subject | white matter | |
| dc.subject | Institute on Aging and Lifelong Health | |
| dc.subject.department | Department of Psychology | |
| dc.subject.department | School of Medical Sciences | |
| dc.subject.department | Division of Medical Sciences | |
| dc.title | Resting State BOLD Variability Is Linked to White Matter Vascular Burden in Healthy Aging but Not in Older Adults With Subjective Cognitive Decline | en_US |
| dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- scarapicchia_vanessa_Front.Human.Neuro_2019a.pdf
- Size:
- 1.28 MB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 2 KB
- Format:
- Item-specific license agreed upon to submission
- Description: